Please assess the completion status of the following clinical trial:

Trial Title: Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes.~* Presence of liver steatosis diagnosed by ultrasound or transient elastography (Fibroscan®)~* Age 30-75 years.~* HbA1c 7.5- 9.5 for at least 8 weeks prior to screening.~* Stable diabetes therapeutic regimen consisting of either diet, oral hypoglycemic agents with or without insulin for 8 weeks prior to randomization.~Exclusion Criteria:~* Body mass index \> 40 kg/m2~* Serum creatinine ≥180mmol/L or estimated glomerular filtration rate \< 30 ml/min.~* Presence of any serious concomitant disease, such as a pulmonary disease or malignant disorders.~* Current daily alcohol ingestion ≥20 g.~* Hepatotoxic drugs.~* Presence of other chronic liver disease other than nonalcoholic fatty liver disease, including hepatitis B virus and hepatitis C virus infection, hemochromatosis, Wilson's disease, alfa-1 antitrypsin deficiency, autoimmune hepatitis.~* Women seeking pregnancy.~* Current use or previous use within 6 months of vitamin E or pioglitazone

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): All subjects will be given placebo identically matched with regard to shape, color and taste. They will be given one tablet/day for 2 weeks and then two tablets/day for the duration of sudy.
- Diacerein (Type: EXPERIMENTAL): All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.

Based on this trial design, predict the completion outcome and termination type (if applicable).